Somatrem Pregnancy and Breastfeeding Warnings
Brand names: Protropin
Somatrem Pregnancy Warnings
Somatrem has been assigned to pregnancy category C by FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Somatrem is only recommended for use during pregnancy when benefit outweighs risk.
One study has suggested that human growth hormone does not cross the placenta in the direction from mother to fetus.
Somatrem Breastfeeding Warnings
There are no data on the excretion of somatrem into human milk. However, it is not expected that somatrem, a large, molecular-weight protein, would be able to pass in any significant amount into breast milk. The manufacturers recommend that caution be used when administering somatrem to nursing women.
Recombinant human growth hormone has been studied as an agent to increase production of milk in mothers of premature infants. No adverse effects were seen in either the mothers or infants and no changes were noted in milk constituents.
See also
References for pregnancy information
- Gitlin D, Kumate J, Morales C (1965) "Metabolism and maternofetal transfer of human growth hormone in the pregnant woman at term." J Clin Endocrinol Metab, 25, p. 1599-608
- (2001) "Product Information. Protropin (somatrem)." Genentech
References for breastfeeding information
- Milsom SR, Breier BH, Gallaher BW, Cox VA, Gunn AJ, Gluckman PD (1992) "Growth hormone stimulates galactopoiesis in healthy lactating women." Acta Endocrinol (Copenh), 127, p. 337-43
- Gunn AJ, Gunn TR, Rabone DL, Breier BH, Blum WF, Gluckman PD (1996) "Growth hormone increases breast milk volumes in mothers of preterm infants." Pediatrics, 98, p. 279-82
- (2001) "Product Information. Protropin (somatrem)." Genentech
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
